Working… Menu
Trial record 1 of 4 for:    atara | PTLD
Previous Study | Return to List | Next Study

Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab (MATCH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03392142
Recruitment Status : Completed
First Posted : January 5, 2018
Last Update Posted : March 26, 2021
Information provided by (Responsible Party):
Atara Biotherapeutics

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 16, 2021
Actual Study Completion Date : February 16, 2021